A5091129809- Bladder and Urothelial Cancer Treatments
- Renal cell carcinoma treatment
- Nutrition and Health in Aging
- Renal and related cancers
- Urinary and Genital Oncology Studies
- Frailty in Older Adults
- Multiple and Secondary Primary Cancers
- Prostate Cancer Diagnosis and Treatment
- Prostate Cancer Treatment and Research
- Urological Disorders and Treatments
- Cancer Genomics and Diagnostics
- Body Composition Measurement Techniques
- Cancer Diagnosis and Treatment
- Economic and Financial Impacts of Cancer
- Health Systems, Economic Evaluations, Quality of Life
- Diversity and Career in Medicine
- Testicular diseases and treatments
- Pancreatic and Hepatic Oncology Research
- Urologic and reproductive health conditions
- Cancer survivorship and care
- Colorectal Cancer Surgical Treatments
- Health and Medical Research Impacts
- Cancer Immunotherapy and Biomarkers
- Radiomics and Machine Learning in Medical Imaging
- Global Cancer Incidence and Screening
University of Washington
2018-2025
Fred Hutch Cancer Center
2020-2025
University of Washington Medical Center
2019-2024
Seattle Cancer Care Alliance
2018-2023
Seattle University
2019-2023
Harborview Medical Center
2023
Seattle Children's Hospital
2022
Emory University
2014-2021
European Association of Urology
2021
John H. Stroger, Jr. Hospital of Cook County
2016-2020
Infantile hemangioma is a benign endothelial tumor composed of disorganized blood vessels. It exhibits unique life cycle rapid postnatal growth followed by slow regression to fibrofatty residuum. Here, we have reported the isolation multipotential stem cells from tissue that give rise hemangioma-like lesions in immunodeficient mice. Cells were isolated based on expression cell marker CD133 and expanded single as clonal populations. The CD133-selected generated human vessels 7 days after...
BACKGROUND The authors evaluated sarcopenia as a predictor of cancer‐specific survival (CSS) and overall (OS) among patients with urothelial cancer the bladder undergoing radical cystectomy (RC). METHODS lumbar skeletal muscle index (SMI) 205 treated RC for between 2000 2007 was measured. Sarcopenia classified according to international consensus definitions (SMI < 55 cm 2 /m men 39 women). CSS OS were estimated using Kaplan‐Meier method compared log‐rank test. Variables associated...
The purpose of this guideline is to provide a useful reference on the effective evidence-based diagnoses and management non-metastatic upper tract urothelial carcinoma (UTUC).The Pacific Northwest Evidence-based Practice Center Oregon Health & Science University (OHSU) team conducted searches in Ovid MEDLINE (1946 March 3rd, 2022), Cochrane Central Register Controlled Trials (through January Database Systematic Reviews 2022). were updated August 2022. When sufficient evidence existed, body...
Purpose The National Comprehensive Cancer Network (NCCN) and American Urological Association (AUA) provide guidelines for surveillance after surgery renal cell carcinoma (RCC). Herein, we assess the ability of to capture RCC recurrences determine duration required 90%, 95%, 100% recurrences. Patients Methods We evaluated 3,651 patients who underwent M0 between 1970 2008. were stratified as AUA low risk (pT1Nx-0) partial (LR-partial) or radical nephrectomy (LR-radical) moderate/high (M/HR;...
We evaluate the association between severe skeletal muscle deficiency or sarcopenia, and disease progression, cancer specific mortality all cause in patients with localized renal cell carcinoma treated radical nephrectomy.The baseline lumbar index of 387 nephrectomy for nonmetastatic 2000 2010 was measured on preoperative computerized tomography. Sarcopenia classified according to gender consensus definitions as male-skeletal less than 55 cm(2)/m(2) female-skeletal 39 cm(2)/m(2)....
There is a significant unmet need for new and efficacious therapies in urothelial cancer (UC). To provide recommendations on appropriate clinical trial designs across disease settings UC, the Society Immunotherapy of Cancer (SITC) International Bladder Group (IBCG) convened multidisciplinary, international consensus panel.Through open communication scientific debate small- whole-group settings, surveying, responses to questionnaires, panel developed optimal definitions state, end points,...
Purpose The appropriate duration of surveillance for renal cell carcinoma (RCC) after radical or partial nephrectomy remains unknown, and evidence to support current guidelines are lacking. Herein, we provide an approach that balances the risk recurrence versus non-RCC death. Patients Methods We identified 2,511 patients who underwent surgery M0 RCC between 1990 2008. were stratified analysis by pathologic stage (pT1Nx-0, pT2Nx-0, pT3/4Nx-0, pTanyN1), relapse location (abdomen, chest, bone,...
To evaluate the clinical and radiographic predictors of need for partial or circumferential resection inferior vena cava (IVC) requiring complex vascular reconstruction during venous tumour thrombectomy renal cell carcinoma (RCC).Data were collected on 172 patients with RCC IVC (levels I-IV) thrombus who underwent radical nephrectomy at Mayo Clinic between 2000 2010. Preoperative imaging was re-reviewed by one two radiologists blinded to details patient's surgical procedure. Univariable...
No AccessJournal of UrologyAdult Urology1 May 2015Mortality after Radical Cystectomy: Impact Obesity Versus Adiposity Adjusting for Skeletal Muscle Wasting Sarah P. Psutka, Stephen A. Boorjian, Michael R. Moynagh, Grant D. Schmit, Igor Frank, Alonso Carrasco, Suzanne B. Stewart, Robert Tarrell, Prabin Thapa, and Matthew K. Tollefson PsutkaSarah Psutka Department Urology, Mayo Clinic, Rochester, Minnesota More articles by this author , BoorjianStephen Boorjian MoynaghMichael Moynagh...
Multiple definitions of biochemical recurrence for prostate cancer exist after radical prostatectomy, and variation continues in outcome reporting secondary treatment initiation. We reviewed long-term prostatectomy outcomes to assess the most appropriate specific antigen cut point that predicts future disease progression.We identified 13,512 patients with cT1-2N0M0 who underwent between 1987 2010. Single points 0.2, 0.3, 0.4 0.5 ng/ml or greater, as well confirmatory value 0.2 greater...